Gelesis, a biotechnology company focused on treating chronic diseases related to the gastrointestinal tract, has secured $64.3 million in funding. Vitruvian Partners led the round.
Source: Press Release
Gelesis picks up $64.3 mln
Gelesis, a biotechnology company focused on treating chronic diseases related to the gastrointestinal tract, has secured $64.3 million in funding.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: